Nature Communications (Feb 2021)
Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
- Jing Liu,
- Ying Xie,
- Jing Guo,
- Xin Li,
- Jingjing Wang,
- Hongmei Jiang,
- Ziyi Peng,
- Jingya Wang,
- Sheng Wang,
- Qian Li,
- Linquan Ye,
- Yuping Zhong,
- Qiguo Zhang,
- Xiaozhi Liu,
- David M. Lonard,
- Jin Wang,
- Bert W. O’Malley,
- Zhiqiang Liu
Affiliations
- Jing Liu
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Ying Xie
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Jing Guo
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Xin Li
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Jingjing Wang
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Hongmei Jiang
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Ziyi Peng
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Jingya Wang
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Sheng Wang
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- Qian Li
- Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Tianjin Key Laboratory of Cancer Prevention and Therapy; Tianjin’s Clinical Research Center for Cancer
- Linquan Ye
- Center for Translational Research in Hematological Malignancies, Cancer Center, Houston Methodist Hospital
- Yuping Zhong
- Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University
- Qiguo Zhang
- Department of Hematology, the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Xiaozhi Liu
- Central Laboratory, Tianjin Key Laboratory of Epigenetics for Organ Development of Premature Infants, The Fifth Central Hospital of Tianjin
- David M. Lonard
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Baylor College of Medicine
- Jin Wang
- Department of Pharmacology and Chemical Biology
- Bert W. O’Malley
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Baylor College of Medicine
- Zhiqiang Liu
- The province and ministry co-sponsored collaborative innovation center for medical epigenetics; Tianjin Key Laboratory of Cellular Homeostasis and Human Diseases; Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University
- DOI
- https://doi.org/10.1038/s41467-021-21386-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
The mechanisms behind acquired resistance to the proteasome inhibitor bortezomib in multiple myeloma remain to be elucidated. Here, the authors show that the histone methyltransferase NSD2 stabilized SRC-3 protein levels, promotes its phase separation and alters H3K36me2 at certain gene promoters resulting in a transcriptional profile that favors resistance of myeloma cells to bortezomib.
